Yazar "Beypinar, Ismail" için listeleme
-
Are they all the same? Different effects of opioid types on survival in metastatic NSCLC receiving nivolumab
Balcik, Onur Yazdan; Beypinar, Ismail; Urvay, Semiha; Urun, Muslih; Ercek, Berrak; Yildiz, Canan; Araz, Murat (E-Century Publishing Corp, 2025)The aim of this study was to evaluate the effects of concurrent opioid analgesic (OA) use and types of OA on progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving ... -
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
Beypinar, Ismail; Demir, Hacer; Yaslikaya, Sendag; Koseci, Tolga; Demir, Bilgin; Colak, Gokhan; Agaoglu, Ahmet Burak (Springer, 2024)Purpose In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi ... -
Is The COVID-19 Pandemic Reason, Shortage Result? A Survey Study on Drug Shortages in Turkish Oncology Clinics
Aim: The rapid development of the drug industry led to a great spectrum of medical treatment, especially in oncology practice. The prescribed drug alternations increased three times in the United States. Also, the increased ... -
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study
Uysal, Mukremin; Saglam, Sezer; Beypinar, Ismail; Saglam, Esra Kaytan; Mammadov, Elkhan; Ocak, Birol; Aybi, Ozge (Taylor & Francis Inc, 2025)The goal of this study was to look at the long-term survival outcomes and clinical characteristics of stage II/III locally advanced rectal cancer (LARC) patients who acquired pathological complete response (pCR) following ... -
Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?
Beypinar, Ismail; Urvay, Semiha; Urun, Muslih; Ercek, Berrak; Demir, Hacer; Yildiz, Canan; Araz, Murat (Springer Heidelberg, 2025)Background Although there are multiple treatment options, oncologists lack appropriate biomarkers for determining the efficacy and toxicity of immunotherapy. In this study, we aimed to use a combination of the clinical ... -
The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma
Uysal, Mukremin; Beypinar, Ismail; Araz, Murat (Wolters Kluwer Medknow Publications, 2024)Background: The discovery of the epidermal growth factor receptor (EGFR) mutation, especially in adenocarcinoma, has led to a major change in the treatment of non-small-cell lung cancer (NSCLC). This study investigated the ... -
The evaluation of vaccination status and the factors affecting vaccination in cancer patients
Aim: Coronavirus disease 2019 (COVID-19) pandemic increased the mortality of cancer patients by causing direct infection or collateral damage to the healthcare system. After the development of effective vaccines against ... -
The Utility of the Cachexia Index and the Modified Glasgow Score in Young Patients With Breast Cancer
Beypinar, Ismail; Demir, Hacer; Culha, Yasar; Kaya, Furkan (Springernature, 2024)Background Breast cancer is the most common cancer in women. Body composition and inflammatory markers are increasingly important for predicting cancer prognosis. The Cancer Cachexia Index (CXI) and the modified Glasgow ...
